Registry study following adults with acute myeloid leukemia and related blood cancers
Collects health records and samples from adults with newly diagnosed or relapsed acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Key facts
- Where
- Graz, Innsbruck, Linz, Rankweil, Salzburg, and Vienna, AustriaSee the 8 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old are you?
Source: NCT01252485, who can take part
Where in Austria
- Medizinische Universität GrazGraz, AustriaTaking people
- Medizinische Universität InnsbruckInnsbruck, AustriaTaking people
- Kepler Universitatsklinikum GmbHLinz, AustriaTaking people
- Krankenhaus der Elisabethinen Linz GmbHLinz, AustriaTaking people
- Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.Linz, AustriaNo longer taking part
- Landeskrankenhaus FeldkirchRankweil, AustriaTaking people
- Universitätsklinikum der PMU Landeskrankenhaus SalzburgSalzburg, AustriaTaking people
- Hanuschkrankenhaus WienVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Ulm
- Trial code
- NCT01252485
- Record updated
- 5 January 2026
- Original description
This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasmsRead full original descriptionShow less
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms
Investigator's sites: 80-90 sites in Germany and Austria
Estimated duration of observation of an individual patient:
10 years maximum
Objectives
* To register all patients with AML and related neoplasms, newly diagnosed or relapsed/refractory in all AMLSG participating centers (completeness) * To perform rapid analyses of disease-related genetic markers (incidences, treatment recommendations) * To assess patient and family history, as well as patient characteristics * To evaluate treatment response (CR, CRh, CRi) and outcome data (event-free survival [EFS], relapse-free survival [RFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS]) * To evaluate the impact of measurable residual disease (MRD) by different methods * To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) * To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue; e.g., skin biopsy, finger nails, hairs, sputum, or urine)
Inclusion: Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification; Age ≥ 18 years. There is no upper age limit; Signed written informed consent.
Exclusion: Severe neurological or psychiatric disorder interfering with ability to give an informed consent; No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation; No consent for biobanking of patient's biological specimens and performance of analyses on stored material.